Physician profile
Aneisha Crossbourne
NPI 1396900882
$1,500.28
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $360 · 2021: $454 · 2022: $162 · 2023: $162 · 2024: $27.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $189.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $638.74 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $312.15 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $102.59 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $95.86 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $79.59 | 2019-2020 | |
| Allergan, INC. | $74.17 | 2019-2020 | |
| Abbvie INC. | $68.85 | 2021-2023 | Dalvance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.16 | 2019-2021 | |
| Ascensia Diabetes Care US INC. | $49.75 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.42 | 2023-2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aneisha Crossbourne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.